(±)-Carbinoxamine

(±)-Carbinoxamine (72 h) potently inhibits infection of MDCK cells by multiple influenza A strains (H7N9, H1N1 2009, H1N1 1934, H3N2) and one influenza B strain (BY), with IC₅₀ values ranging from 3.56 to 15.54 μM^[1].
(±)-Carbinoxamine (0-1000 μM; 72 h) exhibits low cytotoxicity against MDCK cells, with a CC₅₀ of 297.30 μM, thus showing a high selection index against various influenza virus strains^[1].
(±)-Carbinoxamine (20 μM; 0-12 h) inhibits infection of MDCK cells by A/Shanghai/37T/2009 (H1N1) at the early stage of the viral life cycle; the inhibition rate reaches 99% when added at 0.5 h post-infection, and drops to 23% when added at 4 h post-infection^[1].
(±)-Carbinoxamine (48 h) specifically inhibits the entry of A/Shanghai/4664T/2013 (H7N9) pseudovirus into MDCK cells, with an IC₅₀ of 8.98 μM, and does not affect the entry of other pseudoviruses or HIV-1^[1].
(±)-Carbinoxamine (1.6-100 μM; 1.5 h) does not inhibit the neuraminidase activity of A/Puerto Rico/8/1934 (H1N1) virus even at concentrations as high as 100 μM^[1].
(±)-Carbinoxamine (12 h) reduces viral RNA synthesis in a dose-dependent manner in MDCK cells infected with the A/Puerto Rico/8/1934 (H1N1) virus^[1].
(±)-Carbinoxamine (10 μM; 12 h) reduces the number of NP-positive MDCK cells infected with A/Puerto Rico/8/1934 (H1N1) virus^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.